Scarica l'app Stockscreener
157.36
1.26%
1.8688
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$155.49
Aprire:
$157.15
Volume 24 ore:
468.39K
Relative Volume:
0.28
Capitalizzazione di mercato:
$300.14B
Reddito:
$54.66B
Utile/perdita netta:
$13.58B
Rapporto P/E:
22.43
EPS:
7.0171
Flusso di cassa netto:
$16.05B
1 W Prestazione:
+0.46%
1M Prestazione:
+5.55%
6M Prestazione:
+10.89%
1 anno Prestazione:
+28.93%
Intervallo 1D:
$156.53
$157.93
Intervallo di 1 settimana:
$153.22
$160.57
Portata 52W:
$112.34
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Nome
Novartis Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVS vs LLY, JNJ, ABBV, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
157.30 | 305.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,235.71 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.13 | 633.19B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
257.32 | 461.26B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.04 | 319.99B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Argus | Hold → Buy |
| 2026-01-27 | Iniziato | Citigroup | Buy |
| 2026-01-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-12 | Downgrade | Goldman | Neutral → Sell |
| 2025-08-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Downgrade | UBS | Buy → Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Underweight |
| 2025-02-04 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-09-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-09-03 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-19 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-23 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-09-25 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-05 | Aggiornamento | Stifel | Hold → Buy |
| 2022-09-15 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-05-09 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Ripresa | Citigroup | Buy |
| 2021-12-14 | Downgrade | Redburn | Buy → Neutral |
| 2021-12-06 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Iniziato | Bernstein | Mkt Perform |
| 2021-03-10 | Downgrade | Argus | Buy → Hold |
| 2021-02-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2020-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-03-10 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-04-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-04-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2018-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Reiterato | Leerink Partners | Outperform |
| 2017-12-06 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Iniziato | Liberum | Buy |
Mostra tutto
Novartis Ag Adr Borsa (NVS) Ultime notizie
Why Does Novartis AG-Sponsored ADR (NYSE:NVS) Track the NYSE Composite? - Kalkine Media
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout - ChartMill
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition - sharewise.com
Novartis to acquire Myricx Bio for $1.5 billion - grafa.com
10 Newly Overvalued Stocks this Week - Morningstar
NVSNovartis AG ADR Options - Finviz
NOTA Forecast — Price Target — Prediction for 2027 - TradingView
Novartis outlines growth path as pipeline and US exposure support long-term story - AD HOC NEWS
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis stock holds steady after EAACI Rhapsido update. US trading stays in view. - AD HOC NEWS
Novartis consensus picture on SIX, analysts keep a neutral view on the stock - AD HOC NEWS
Novartis opens the week with a cautious sector backdrop, shares in focus alongside Roche - AD HOC NEWS
Price to earnings forward of Novartis AG Sponsored ADR – MUN:NOTA - TradingView
Novartis oncology partnership with Antares, shares trade near analyst targets - AD HOC NEWS
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSC) - TradingView
Novartis focuses on oncology pipeline, shares track SMI pharma peers - AD HOC NEWS
907122 Forecast — Price Target — Prediction for 2027 - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSD) - TradingView
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR Actuals & Estimates (BMFBOVESPA:N1VS34) - TradingView
NVS/N Forecast — Price Target — Prediction for 2027 - TradingView
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Sahm
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
Novartis highlights pipeline progress, shares trade steadily on NYSE - AD HOC NEWS
Novartis AG Stock (NVS) Closed Up by 3.04% on Jun 23: What Signal Does It Send? - TradingKey
Novartis refines India unit strategy, shares in focus on SIX trading - AD HOC NEWS
Novartis strategy highlighted by remibrutinib and Sandoz spin-off, shares steady on SIX - AD HOC NEWS
Why Novartis lets Cosentyx step beyond psoriasis in everyday care - AD HOC NEWS
NOVARTIS AG-SPONSORED ADR (NVS) Stock Chart - ChartMill
Cash flow from operating activities of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Enterprise value to EBITDA ratio of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Income Statement – BCBA:NVS.CI - TradingView
Preferred dividends of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG Stock (CH0012005267): Earnings in focus for US investors - AD HOC NEWS
Novartis AG Stock (CH0012005267): Analyst Targets and SMI Role Keep Shares in Focus - AD HOC NEWS
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study - TradingView
Novartis AG Stock (CH0012005267): In focus on a quiet Sunday session - AD HOC NEWS
Why is Novartis stock rallying today? - Investing.com
Novartis Ag Adr Azioni (NVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):